KELLY

OFFICIAL TITLE: A PHASE II STUDY OF PEMBROLIZUMAB AND ERIBULIN IN PATIENTS WITH HRPOSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES.

AACR 2018 – DOWNLOAD THE POSTER

PROJECT DETAILS

THIS A MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH ERIBULIN IN FEMALE PATIENTS OLDER THAN 18 YEARS OLD WITH HORMONE RECEPTOR-(HR)POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AT LEAST ONE, BUT NOT MORE THAN TWO, PRIOR CHEMOTHERAPEUTIC REGIMENS FOR TREATMENT OF LOCALLY RECURRENT AND/OR METASTATIC DISEASE. PRIOR THERAPY MUST HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE. PRIOR ANTI-HORMONAL THERAPY IN THE METASTATIC DISEASE SETTING IS MANDATORY.

THE NUMBER OF PATIENTS TO BE INCLUDED IS 44 PATIENTS AT 11 SITES. ALL ELIGIBLE PATIENTS WILL BE TREATED WITH MK3475 (PEMBROLIZUMAB) 200 MG ON DAY 1 OF EACH 21-DAY CYCLE AND ERIBULIN 1.23 MG/M2 (EQUIVALENT TO ERIBULIN MESYLATE AT 1.4 MG/M2) ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE.

 

KELLY AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

BREAST

II

44

11

Spain

Recruitment  closed

SABCS 2019 – DOWNLOAD THE POSTER

KELLY SITES

SPAIN

Hospital Clínico Universitario de Valencia

SPAIN

Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona

SPAIN

Hospital Parc Taulí

SPAIN

Hospital Clínic i Provincial de Barcelona

SPAIN

MD Anderson Cancer Center Madrid

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Complejo Hospitalario de Navarra

SPAIN

Complejo Hospitalario Universitario A Coruña (CHUAC)

SPAIN

Hospital Universitario Virgen del Rocío

SPAIN

Hospital Clínico Universitario Virgen de la Arrixaca

SPAIN

Hospital Arnau de Vilanova de Valencia